Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study

Davila, J. A.; Morgan, R. O.; Shaib, Y.; McGlynn, K. A.; El-Serag, H. B.
April 2005
Gut;Apr2005, Vol. 54 Issue 4, p533
Academic Journal
Background: Diabetes has been associated with an increased risk of hepatocellular carcinoma (HCC) in studies of referred patients. This is the first population based case control study in the USA to examine this association while adjusting for other major risk factors related to HCC. Methods: We used the Surveillance Epidemiology and End-Results Program (SEER)-Medicare linked database to identify patients aged 65 years and older diagnosed with HCC and randomly selected non- cancer controls between 1994 and 1999. Only cases and controls with continuous Medicare enrolment for three years prior to the index date were examined. Inpatient and outpatient claims files were searched for diagnostic codes indicative of diabetes, hepatitis C virus (HCY), hepatitis B virus (HBY), alcoholic liver disease, and haemochromatosis. HCC patients without these conditions were categorised as idiopathic. Unadjusted and adjusted odds ratios were calculated in logistic regression analyses. Results: We identified 2061 HCC patients and 6183 non-cancer controls. Compared with non-cancer controls, patients with HCC were male (66% v 36%) and non-White (34% v 18%). The proportion of HCC patients with diabetes (43%) was significantly greater than non-cancer controls (19%). In multiple logistic regression analyses that adjusted for demographics features and other HCC risk factors (HCY, HBV, alcoholic liver disease, and haemochromatosis), diabetes was associated with a threefold increase in the risk of HCC. In a subset of patients without these major risk factors, the adjusted odds ratio for diabetes declined but remained significant (adjusted odds ratio 2.87 (95% confidence interval 2.49-3.30)). A significant positive interaction between HCY and diabetes was detected (p<0.0001). Similar findings persisted in analyses restricted to diabetes recorded between two and three years prior to HCC diagnosis. Conclusions: Diabetes is associated with a 2-3-fold increase in the risk of HCC, regardless of the presence of other major HCC risk factors. Findings from this population based study suggest that diabetes is an independent risk factor for HCC.


Related Articles

  • Liver Cancer Incidence Is Growing Faster Than Incidence of Other Cancers. Hogle, William P. // Clinical Journal of Oncology Nursing;Feb2005, Vol. 9 Issue 1, p25 

    Reports on the increase in the incidence of liver cancer in the U.S., as reported by the Liver Cancer Network. Percentage of liver cancer patients involved in the network's study that have hepatitis C or an underlying liver disease; Ineffectiveness of chemotherapy on liver cancer.

  • Case report: effect of antileishmanial treatment on hepatitis C viraemia in avisceral leishmaniasis patient with chronic hepatitis C. F.^Precone, David; Stornaiuolo, Gianfranca; Galante, Domenico; Amato, Anna; Gradoni, Luigi; Gaeta, Giovanni B. // Transactions of the Royal Society of Tropical Medicine & Hygiene;Sep2003, Vol. 97 Issue 5, p559 

    Abstract: We describe a case of Mediterranean visceral leishmaniasis (VL) in a patient with pre-existing chronichepatitis C, which caused high hepatitis C virus (HCV) plasma concentration and was followed by a rapidly growing hepatocellular carcinoma (HCC). The high HCV load was drastically and...

  • Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. Kobayashi, Masahiro; Ikeda, Kenji; Arase, Yasuji; Suzuki, Yoshiyuki; Suzuki, Fumitaka; Akuta, Norio; Hosaka, Tetsuya; Murashima, Naoya; Saitoh, Satoshi; Someya, Takashi; Tsubota, Akihito; Kumada, Hiromitsu // Journal of Gastroenterology;2008, Vol. 43 Issue 1, p63 

    Background. A phase II randomized controlled trial was conducted in patients with compensated liver cirrhosis to investigate the inhibitory effect of branchedchain amino acid (BCAA) granules for oral use (TK-98) on disease progression. Methods. Patients who had compensated liver cirrhosis due to...

  • Factors Associated with Interest in Initiating Treatment for Hepatitis C Virus (HCV) Infection among Young HCV-Infected Injection Drug Users. Strathdee, Steffanie A.; Latka, M.; Campbell, J.; O'Driscoll, P. T.; Golub, E. T.; Kapadia, F.; Pollini, R. A.; Garfein, R. S.; Thomas, D. L.; Hagan, H. // Clinical Infectious Diseases;4/15/2005 Supplement, Vol. 40, pS304 

    Objective. We sought to identify factors associated with interest in receiving therapy for hepatitis C virus (HCV) infection among HCV-infected injection drug users (IDUs) in 3 United States cities. Methods. IDUs aged 18-3 5 years who were HCV-infected and seronegative for human immunodeficiency...

  • A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. Kusakabe, Atsunori; Tanaka, Yasuhito; Orito, Etsuro; Sugauchi, Fuminaka; Kurbanov, Fuat; Sakamoto, Tomoyuki; Shinkai, Noboru; Hirashima, Noboru; Hasegawa, Izumi; Ohno, Tomoyoshi; Ueda, Ryuzo; Mizokami, Masashi // Journal of Gastroenterology;Apr2007, Vol. 42 Issue 4, p298 

    In Japan, approximately 10% of hepatocellular carcinoma (HCC) patients are negative for both hepatitis B surface antigen (HBsAg) and antibodies to hepatitis C virus (anti-HCV), i.e., they constitute the so-called category of non-B non-C (NBNC) HCC. Little is known about the characteristics of...

  • Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma. Bihrer, Verena; Waidmann, Oliver; Friedrich-Rust, Mireen; Forestier, Nicole; Susser, Simone; Haupenthal, Jörg; Welker, Martin; Ying Shi; Peveling-Oberhag, Jan; Polta, Andreas; von Wagner, Michael; Radeke, Heinfried H.; Sarrazin, Christoph; Trojan, Jörg; Zeuzem, Stefan; Kronenberger, Bernd; Piiper, Albrecht // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Background: MicroRNA-21 (miR-21) is up-regulated in tumor tissue of patients with malignant diseases, including hepatocellular carcinoma (HCC). Elevated concentrations of miR-21 have also been found in sera or plasma from patients with malignancies, rendering it an interesting candidate as...

  • COMMENTARY: Peginterferon &Alfa;-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections. Koretz, Ronald L. // ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p10 

    The article reports that peginterferon &Alfa;-2a improved the hepatitis C virologic (HCV) response in concurrent HIV and chronic hepatitis C virus infections. Regardless of whether progression of liver disease is more rapid, the fact that HIV patients are living longer allows more time for...

  • Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection. Uka, Kiminori; Suzuki, Fumitaka; Akuta, Norio; Sezaki, Hitomi; Suzuki, Yoshiyuki; Hosaka, Tetsuya; Someya, Takashi; Kobayashi, Masahiro; Saitoh, Satoshi; Arase, Yasuji; Ikeda, Kenji; Kumada, Hiromitsu // Journal of Gastroenterology;May2006, Vol. 41 Issue 5, p470 

    Background. Suppression of the progression to cirrhosis and hepatocellular carcinoma is important, especially for young hepatitis C virus (HCV)-infected patients. The aim of this study was to analyze the response to interferon (IFN) monotherapy in young HCV patients. Methods. Between 1989 and...

  • Costs of cancer. Mortland, Shannon // Crain's Cleveland Business;8/30/2004, Vol. 25 Issue 35, p1 

    Like many oncologists, physician David Fishman wonders whether he'll be administering chemotherapy treatments to cancer patients in his office much longer. About 80% of chemotherapy treatments are conducted in a physician's office, but many private-practice oncologists fear they won't be able to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics